2.2 Sanofi Group company and its csr program. Results and Perspectives.

The Sanofi Group is represented in Russia by the following companies: Sanofi, Sanofi Pasteur, Zentiva, Genzyme, Merial. Sanofi products have been available to Russian patients for over 40 years . Currently, Sanofi Russia offers patients a wide range of medicines for socially significant diseases such as diabetes, cancer, cardiovascular disease and thrombosis, as well as diseases of the central nervous system. The world’s largest vaccine manufacturer with a portfolio including vaccines against 20 infectious diseases. Sanofi Pasteur has been in the Russian market since 1992 and is now ranked among the leaders of this segment in Russia offering Russian patients 9 different vaccines. Sanofi’s generic pharmaceutical platform since 2009, it is the third-largest manufacturer of generic drugs in Europe and one of the fastest growing companies. Its diversified portfolio comprises high-quality, affordable medicines and covers all major areas of medicine. Zentiva has been in the Russian market since 2003.

Medicines to treat rare diseases in the Sanofi Russia portfolio are represented by products from Genzyme - one of the leading biotech companies in the world which joined the Sanofi group in 2011. Veterinary drugs produced by Merial can also be found in Sanofi Russia’s portfolio. Merial, which joined Sanofi in 2011, is a world leader in the field of veterinary medicine that focuses on the development and production of innovative products and solutions to protect the health of animals.

Sanofi is a global integrated healthcare leader and the needs of our patients are at the very core of our work. Our mission is to improve the health of patients, improve the quality of their lives and satisfy

their needs. As part of the Company’s strategy, Sanofi takes on social, environmental and ethical obligations. Their global strategy focuses on four main categories: “Patient”, “Ethics”, “People” and “Planet”.

Patient	Fighting diabetes as part of the program “Every day is your day!” Treatment of cardiovascular diseases in the “Heart Help” program Fighting venous complications as part of the program “Safe zone from venous thromboembolism” Treating patients with chronic kidney disease: program “Choice for Life” Fighting epilepsy as part of the program “Epicenters” and “Attention, epilepsy!” Nationwide program to help patients with breast cancer “Giving Life a Chance” The program “Help Children with Acute Lymphoblastic Leukemia” The program “School of Future Mothers” The program “Educational Campaign for Parents” Increasing access to high-quality medicines Fighting counterfeit and adulterated medicines Safety drug monitoring Protecting the health of animals
Ethics	Ethics in clinical trials Responsible marketing Restrictions on advertising of medicines The control mechanism over the printed promotional materials Fighting corruption
People	Attracting personnel Development and Training Assessment of staff performance The employee compensation system Life insurance program (including accident insurance and insurance against lifethreatening diseases) Travel insurance program for foreign travel and trips within the territory of Russia Additional payment for periods of temporary disability Maternity support policy (special insurance programs for mothers and children as well as compensation payments when the employee takes a leave from work) Program for children of company employees, “Holiday Exchange Program” Financial assistance program for children of employees who find themselves in difficult situations within the framework of the Sanofi Children Association Increasing the level of engagement and staff satisfaction Forming a corporate culture Project Innovation Box Health and safety of employees in the workplace
Planet	Reducing energy consumption and carbon emissions Management of water resources Pharmaceuticals in the environment, including processing issues

Public awareness programs, educational programs for healthcare professionals and patients, and programs for patient care are a priority area for the Group. The results of the “materiality test”1 conducted in December 2012 confirmed the importance of this area for the company’s stakeholders especially in regards to treatment for non-communicable diseases. In the reporting period, 10 programs to improve access to healthcare were conducted. Most of them were launched in 2009 while 1 began in 2012. The number of patients taking part in Sanofi Russia programs is increasing and coverage of Russian regions and cities has been expanded to ensure that more patients benefit from them.

The programs focus on the following key objectives: increasing public awareness of illnesses; improving the skills of specialists in the sphere of healthcare; providing affordable and accessible medicines; educating and informing patients.

The activities of Sanofi Russia are aimed at ensuring the quality of medicines throughout the entire process of distributing pharmaceutical products. The company’s responsibility does not end at the stage of product sales to distributors but extends to ensuring the physical availability of Sanofi drugs in pharmacies and hospitals. Sanofi’s area of responsibility includes all issues related to the quality of medicines that may arise in the course of storage, sale, or transportation of medicines, including their use by end-users.

Sanofi is committed to providing safe and effective products worldwide that are developed, manufactured, distributed, and marketed in compliance with statutory and regulatory requirements and our corporate values. To ensure patients’ safety and satisfy stakeholders’ expectations, the Group upholds the same standards of quality across the globe.

Respect for ethics in clinical trials, one of Sanofi’s primary focuses, is based on providing solid and reliable data, ensuring the welfare of trial participants, and helping build trust in the pharmaceutical industry.

In the selection of candidates, Sanofi Russia adheres to the principle of objectivity and validity of decisions. To this end, the selection of candidates consists of several steps using various assessment tools. Final decisions are made collectively, taking into account the views of all participants in the selection process. The approach to training and development is based on an annual analysis of business needs and the creation of individual development plans (IDP) which are developed for each employee at the beginning of the year based on his strengths and areas for development.

Sanofi Russia has implemented an effective system for remunerating employees aimed at attracting and retaining staff, and motivating employee performance. The level of employee loyalty at Sanofi

Russia remains high. According to a 2012 survey, the employee engagement index at Sanofi Russia is 82%, up 5% from a similar survey in 2010. Thus, 91% of employees take pride in their work at Sanofi Russia and 73% of employees rarely think about changing jobs which is 11% higher than the Russian average.

To safeguard the health of communities everywhere, we continually seek to limit the environmental impact of our activities. The most significant aspects of the impact of Sanofi Russia on the environment in the office are electricity consumption, water consumption and paper usage.

The organization of safe and effective waste management is one of the priorities of Sanofi-Aventis Vostok’s environmental protection activity. In 2012, 97.301 tons of waste were created at the site, most of which fall into low and very low hazard classes (39% and 60%, respectively). Sanofi Russia pays attention to environmental safety in the office and in the factory. The basic document governing the operations of the company in the environmental field is the policy on health, safety and the environment. Plant conservation activities are coordinated by the HSE Committee. The main initiatives to reduce the impact on the environment in the office are the use of motion sensors in warehouses, meeting rooms, bathrooms and faucets.

Sanofi Russia sees the development of performance indicators for topics that are significant from the point of view of CSR as the next step in improving Sanofi Russia’s CSR management. These topics include aspects such as the environment and people. Currently, Sanofi Russia has built a system for recording CSR performance.Thus, the company now records carbon dioxide emissions, energy consumption, and occupational injury statistics. Sanofi Russia pays significant attention to compliance with ethical business practices. The company has built processes to ensure compliance in clinical trials, marketing activities and combating corruption.

It has been no part of our aim to make a comprehensive study of CSR principles in Russian business companies. Nonetheless, we can sum up as follows that the social responsibility presented to society in an open form in its most developed option, that is understood as activities of the companies for three types of responsibility: economic (quality, safety of production and services, and also their physical and price availability), ecological (decrease in harmful emissions and other loads of environment) and social (development of own collective and external social projects, including charity). On the example of the company Sanofi Group we were convinced that activity of the large companies radically changes a situation. Regardless, whether such social activity is caused by desire to become more attractive employer or the supplier for the large companies, or simply ethical belief of owners, this research testifies that the Russian enterprises become more and more socially responsible.

Conclusion

All of us bear a personal responsibility the friend before the friend and before society in which we live. Everything that we do, has impact on others people. Regardless of, whether is company large or small, state or private, its actions infringe on interests large number of interested parties, in which number clients, shareholders enter, workers, suppliers and society in general. In conditions when the fixed grows public attention to the business to operations, the company are more and more compelled to satisfy expectations of those who forms opinion of the public, and also expectation government institutions and clients, to continue successful activity.

In effect, the companies adopt the principles of CSR because they believe that the ethic and socially responsible business gives they have more than chances of success. As at the private businessmen of interested parties it is less, their main effort is directed on satisfaction of inquiries of clients, and also on own ability effectively to satisfy demand of the consumer.

The companies testify that correctly built work within helps social responsibility in achievement of commercial purposes. Especially it is right for big corporations, in which compliance to the legislative to requirements, and also strengthening of reputation and relationship directly affects on increase of a stock value and profitability.

As for the enterprises operated owners, their increase social activity cause the large multinational companies, which even more often demand from the suppliers of commitment to ethic business. Integration corporate social responsibility in the structure of the main business strategy can also to increase appeal of the company in quality employer.

On the example of the company Sanofi Group we were convinced that activity of the large companies radically changes a situation. Regardless, whether such social activity is caused by desire to become more attractive employer or the supplier for the large companies, or simply ethical belief of owners, this research testifies that the Russian enterprises become more and more socially responsible.

It comes the time when all enterprises of private business are compelled to take into account the growing need to do business socially responsible and transparent. Only those, who sensitively and quickly react to changes and also make non-standard decisions, will survive and win.

Bibliography

Newspapers and Magazines:

1. Baron, D. (2007, September). Corporate social responsibility and social entrepreneurship.

Journal of Economics & Management Strategy, 16(3), 683-717.

2. Brown T. J., & Dacin, P. A. (1997, January). The company and the product: Corporate

associations and consumer product responses. Journal of Marketing, 61(1), 68-84.

3. Carroll, A. B. (1979, October). A three-dimensional conceptual model of corporate

performance. Academy of Management Review, 4(4), 497-505.

4. Freeman, R Edward, Jeffrey S. Harrison, Andrew C Wicks, Bidhan L Parmar and Simone de Colle, Stakeholder Theory: The State of the Art, Cambridge: Cambridge University Press, 2010

5. M. Friedman. "The Social Responsibility of Business Is to Increase its Profits." New

York Times. September 13 1970, pp. 122-126.

6. Griffin, J.J. and J.F Mahon. 1997. The Corporate Social Performance and Corporate Financial Performance Debate: Twenty-five years of Incomparable Research. Business and Society, 36(1):5-31.

7. Walton, S. B. (2010, July). Do the right thing: Measuring the effectiveness of corporate

social responsibility. Public Relations Tactics, 17(7), 10-11.

8. McWilliams, A. and D. Siegel. 2001. Corporate Social Responsibility: A Theory of the Firm

Perspective. Academy of Management Review, 26(1):117-127.

Books:

9. Brent D. (David) Beal. 2013. Corporate Social Responsibility: Definition, Core Issues, and Recent Developments

10. Mark S. Schwartz. 2011. Corporate Social Responsibility: An Ethical Approach Paperback

11. Suzanne Benn, Dianne Bolton. 2011. Key Concepts in Corporate Social Responsibility (SAGE Key Concepts series)

24